Allogeneic CD19-targeted CAR-T therapy in refractory systemic lupus erythematosus achieved durable remission
Authors:
Abstract
No abstract availableKeywords
Funding Information
- National Key Research and Development Program of China (2018AAA0100302)
- National Key Research and Development Program of China (2023YJBF-GG02)
- National Key Research and Development Program of China (2023YFC3402000)
- National Natural Science Foundation of China (82330055)
- National Natural Science Foundation of China (32270960)
- National Natural Science Foundation of China (82320108010)
- National Natural Science Foundation of China (81930043)
- National Natural Science Foundation of China (U24A20380)
- National Natural Science Foundation of China (31821003)
- National Natural Science Foundation of China (82271852)
- National Natural Science Foundation of China (82271816)
- Natural Science Foundation of Jiangsu Province (BK20231119)
- Shanghai Municipal Health Commission
- Nanjing Drum Tower Hospital
- Jiangsu Commission of Health
- Science and Technology Commission of Shanghai Municipality (23XD1430600)
- Basic Research Program of Jiangsu Province (BK20243061)
This publication has 25 references indexed in Scilit:
- CD19-targeting CAR T-cell therapy in patients with diffuse systemic sclerosis: a case seriesThe Lancet Rheumatology, 2024
- Allogeneic CD19-targeted CAR-T therapy in patients with severe myositis and systemic sclerosisCell, 2024
- CAR T-cell therapy rescues adolescent with rapidly progressive lupus nephritis from haemodialysisThe Lancet, 2024
- Innovative cellular therapies for autoimmune diseases: expert-based position statement and clinical practice recommendations from the EBMT practice harmonization and guidelines committeeeClinicalMedicine, 2024
- Allogeneic CAR-T cells with of HLA-A/B and TRAC disruption exhibit promising antitumor capacity against B cell malignanciesCancer Immunology, Immunotherapy, 2024
- CAR T-cell therapy in autoimmune diseasesThe Lancet, 2023
- CD19-Targeting CAR T Cells for Myositis and Interstitial Lung Disease Associated With Antisynthetase SyndromeJAMA, 2023
- CD19-targeted CAR T cells in refractory antisynthetase syndromeThe Lancet, 2023
- Anti-CD20–mediated B-cell depletion in autoimmune diseases: successes, failures and future perspectivesKidney International, 2020
- Revision of the International Society of Nephrology/Renal Pathology Society classification for lupus nephritis: clarification of definitions, and modified National Institutes of Health activity and chronicity indicesKidney International, 2018